ESR1 and breast carcinoma: In triple-negative (i.e., estrogen receptor, progesterone receptor and HER2/neu receptor-negative) breast cancer, a highly malignant and therapy-resistant form of breast cancer, CSCs show high levels of Cx26 expression [117].